|
|
Cantharidins induce ER stress and a terminal unfolded protein response in OSCC
|
|
|
|
|
نویسنده
|
xi y. ,garshott d.m. ,brownell a.l. ,yoo g.h. ,lin h.-s. ,freeburg t.l. ,yoo n.g. ,kaufman r.j. ,callaghan m.u. ,fribley a.m.
|
منبع
|
journal of dental research - 2015 - دوره : 94 - شماره : 2 - صفحه:320 -329
|
چکیده
|
Mortality and morbidity associated with oral squamous cell carcinoma (oscc) remain unacceptably high with disfiguring treatment options and a death rate of 1 per hour in the united states. the approval of cituximab for advanced oscc has been the only new treatment for these patients since the 1970s,although it has not significantly increased overall survival. to address the paucity of effective new therapies,we undertook a high-throughput screen to discover small molecules and natural products that could induce endoplasmic reticulum (er) stress and enforce a terminal unfolded protein response (upr) in oscc. the terpenoid cantharidin (cnt),previously used to treat various malignancies in culture-specific medical practices for over 2,000 y,emerged as a hit. cnt and its analog,cantharidic acid,potently induced protein and gene expression profiles consistent with the activation of er stress,the upr,and apoptosis in oscc cells. murine embryonic fibroblasts null for the upr-associated transcription factors atf4 or chop were significantly protected from cnt,implicating a key role for the upr in the death response. these data validate that our high-throughput screen can identify novel modulators of upr signaling and that such compounds might provide a new therapeutic approach to treating patients with oscc. © international & american associations for dental research 2014.
|
کلیدواژه
|
ATF4; cantharide; chemotherapy; CHOP; natural products; UPR
|
آدرس
|
key laboratory of pathiobiology,jilin university,ministry of education,changchun,china,carmen and ann adams department of pediatrics,division of hematology oncology,children's hospital of michigan,detroit,mi, United States, carmen and ann adams department of pediatrics,division of hematology oncology,children's hospital of michigan,detroit,mi, United States, carmen and ann adams department of pediatrics,division of hematology oncology,children's hospital of michigan,detroit,mi, United States, department of otolaryngology,wayne state university,karmanos cancer institute,detroit,mi, United States, department of otolaryngology,wayne state university,karmanos cancer institute,detroit,mi, United States, department of otolaryngology,wayne state university,karmanos cancer institute,detroit,mi, United States, department of otolaryngology,wayne state university,karmanos cancer institute,detroit,mi, United States, degenerative diseases program,sanford burnham medical research institute,san diego,ca,united states,department of pharmacology,university of california medical center,10901 north torrey pines road,san diego,ca, United States, carmen and ann adams department of pediatrics,division of hematology oncology,children's hospital of michigan,detroit,mi, United States, carmen and ann adams department of pediatrics,division of hematology oncology,children's hospital of michigan,detroit,mi,united states,department of otolaryngology,wayne state university,karmanos cancer institute,detroit,mi,united states,developmental therapeutics program,barbara ann karmanos cancer institute,detroit,mi, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|